Literature DB >> 29284292

National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap.

Shi Feng1, Shuang Liu1, Chong Zhu2,3, Mengchun Gong2,4, Yicheng Zhu2,5, Shuyang Zhang2,5.   

Abstract

Rare diseases are major challenges in healthcare and medical research and are the basis of national development strategies in many countries. However, inadequate definition of rare diseases and lags in orphan drug development in China hinder rare disease research. In response, the first National Rare Diseases Registry System of China (NRDRS) was established, and various cohort studies have been launched since 2016. More than 20 top academic institutions in China are currently participating in this joint effort to carry out nationwide registration of rare diseases. The primary objectives are to establish standardization for the registration platform, build biobanks of genomic data, and create partnerships for data sharing and research collaboration. Innovative informatics technologies have been implemented to develop the NRDRS, including employment of ontological and knowledge bases to render standardization and support standard of care. Development of informatics analysis tools will facilitate accurate and more efficient diagnoses for rare diseases. Long-term research collaboration is encouraged to create additional national rare disease networks for research translation and to benefit patients with rare diseases. The NRDRS of China and related cohort studies are anticipated to enlighten rare disease research significantly in China.

Entities:  

Keywords:  cohort study; genomics; medical informatics; patient registry; rare diseases

Mesh:

Year:  2018        PMID: 29284292     DOI: 10.1089/hum.2017.215

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

Review 1.  The case for open science: rare diseases.

Authors:  Yaffa R Rubinstein; Peter N Robinson; William A Gahl; Paul Avillach; Gareth Baynam; Helene Cederroth; Rebecca M Goodwin; Stephen C Groft; Mats G Hansson; Nomi L Harris; Vojtech Huser; Deborah Mascalzoni; Julie A McMurry; Matthew Might; Christoffer Nellaker; Barend Mons; Dina N Paltoo; Jonathan Pevsner; Manuel Posada; Alison P Rockett-Frase; Marco Roos; Tamar B Rubinstein; Domenica Taruscio; Esther van Enckevort; Melissa A Haendel
Journal:  JAMIA Open       Date:  2020-09-11

2.  Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai.

Authors:  Xiaoshu Cai; Hui Yang; Georgi Z Genchev; Hui Lu; Guangjun Yu
Journal:  Orphanet J Rare Dis       Date:  2019-10-22       Impact factor: 4.123

3.  Financing of Rare Diseases and Orphan Drugs in A Sanctioned Country: A Qualitative Study.

Authors:  Seyran Naghdi; Mohammadreza Maleki; Sudabeh Vatankhah
Journal:  Med J Islam Repub Iran       Date:  2022-05-11

4.  Rare disease curative care expenditure-financing scheme-health provider-beneficiary group analysis: an empirical study in Sichuan Province, China.

Authors:  Jia Li; Lian Yang; Yitong Zhang; Hailun Liao; Yuan Ma; Qun Sun
Journal:  Orphanet J Rare Dis       Date:  2022-10-08       Impact factor: 4.303

5.  Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol.

Authors:  Ji He; Jia Yu Fu; Lu Chen; Jing He; Jingxia Dang; Zhangyu Zou; Sha Ma; Nan Li; Dongsheng Fan
Journal:  BMJ Open       Date:  2020-12-04       Impact factor: 3.006

6.  10 years of CEMARA database in the AnDDI-Rares network: a unique resource facilitating research and epidemiology in developmental disorders in France.

Authors:  Claude Messiaen; Caroline Racine; Arnaud Sandrin; Alain Verloes; Laurence Faivre; Ahlem Khatim; Louis Soussand; Sylvie Odent; Didier Lacombe; Sylvie Manouvrier; Patrick Edery; Sabine Sigaudy; David Geneviève; Christel Thauvin-Robinet; Laurent Pasquier; Florence Petit; Massimiliano Rossi; Marjolaine Willems; Tania Attié-Bitach; Pierre-Henry Roux-Levy; Laurent Demougeot; Lilia Ben Slama; Paul Landais; Anne-Sophie Jannot; Christine Binquet
Journal:  Orphanet J Rare Dis       Date:  2021-08-04       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.